Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PKL200
- Development stage
- Preclinical
- Lead developer
- iNtRON Biotechnology
- Modality
- Recombinant Proteins and Enzymes
01
Overview
PKL200 (also known as INT-223) is an engineered endolysin biologic developed by iNtRON Biotechnology using its proprietary itLysin® platform. It is specifically designed for the decolonization of Carbapenem-Resistant Enterobacteriaceae (CRE) within the intestinal tract. PKL200 functions by targeting and enzymatically degrading the peptidoglycan layer of Gram-negative bacteria, leading to rapid osmotic lysis and cell death. The drug candidate has demonstrated broad-spectrum activity against several high-priority pathogens, including *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter cloacae*. In addition to intestinal decolonization, PKL200 is being explored for the treatment of pneumonia and urinary tract infections caused by uropathogenic *Escherichia coli* (UPEC).
Beyond the preview
Go deeper on PKL200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PKL200.